Citadel Advisors
LTRN icon

Citadel Advisors’s Lantern Pharma LTRN Stock Holding History

Citadel Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,300
Closed -$37.3K – 13687
2025
Q4 		$37.3K Sell
12,300
-6,100
-33% -$22.7K ﹤0.01% 12147
2025
Q3 		$80K Buy
18,400
+2,000
+12% +$8.35K ﹤0.01% 11971
2025
Q2 		$51.8K Sell
16,400
-700
-4% -$2.36K ﹤0.01% 11749
2025
Q1 		$60.5K Buy
17,100
+12,500
+272% +$51.9K ﹤0.01% 12102
2024
Q4 		$14.7K Sell
4,600
-35,200
-88% -$121K ﹤0.01% 13395
2024
Q3 		$146K Sell
39,800
-3,000
-7% -$12.4K ﹤0.01% 10596
2024
Q2 		$200K Buy
42,800
+22,900
+115% +$138K ﹤0.01% 9948
2024
Q1 		$175K Buy
19,900
+19,700
+9,850% +$105K ﹤0.01% 10539
2023
Q4 		$856 Sell
200
-2,000
-91% -$7.05K ﹤0.01% 13925
2023
Q3 		$7.5K Buy
2,200
+2,000
+1,000% +$9.08K ﹤0.01% 13254
2023
Q2 		$1.13K Sell
200
-7,300
-97% -$37.7K ﹤0.01% 13982
2023
Q1 		$36.2K Buy
7,500
+700
+10% +$3.68K ﹤0.01% 12550
2022
Q4 		$41.1K Sell
6,800
-4,500
-40% -$22.5K ﹤0.01% 12377
2022
Q3 		$54K Buy
+11,300
New +$60.7K ﹤0.01% 11569

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors's LTRN Position: Q1 2026 in Review

Citadel Advisors sold out of Lantern Pharma (LTRN) in Q1 2026, closing a stake of 32,895 shares — an estimated $99.7K sold.

Citadel Advisors first reported a position in LTRN in Q1 2021 and held it in 11 quarters. The position peaked at $203K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Citadel Advisors reported no remaining Lantern Pharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 32,895 Lantern Pharma shares in Q1 2026, an estimated $99.7K.
  • Citadel Advisors first reported a position in Lantern Pharma in Q1 2021 and held it in 11 quarters.
  • Citadel Advisors's Lantern Pharma position peaked at $203K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.